Latest News and Press Releases

Aardvark to acquire global development and commercialization rights to ADAIR and all intellectual property outside of Europe and licensor rights for the EU Aardvark to leverage ADAIR formulation...

Rapidly advancing clinical pipeline across multiple high-value inflammatory, fibrotic and autoimmune diseases On track to launch a Phase 2a biomarker study evaluating GRI-0621 for the treatment...

Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...

- Live moderated webcast fireside chat today, August 3rd at 11:15 AM ET LA JOLLA, CA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology...

- Live moderated webcast with members of the GRI Bio management team on Thursday, July 27th at 1:00 PM ET LA JOLLA, CA, July 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio”...

- Live moderated webcast with members of the GRI Bio, Inc. management team on Tuesday, July 11th at 2:00 PM ET LA JOLLA, CA, July 05, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI...

- U.S. patent issuance for lead program, GRI-0621, in development for the treatment of idiopathic pulmonary fibrosis (IPF) - Company building a robust global patent estate LA JOLLA, CA, June...

- Live webcast fireside chat on Thursday, June 22nd at 12:00 PM ET LA JOLLA, CA, June 15, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...

Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc....

Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases Leading NKT regulation technology targeting earlier in the inflammatory cascade to...